| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2013-02-26 |
| タイトル |
|
|
タイトル |
Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Oxicam |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
non-steroidal anti-inflammatory drugs (NSAIDs) |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Neuroprotection |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Parkinson’s disease (PD) |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Akt |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
田崎, 嘉一
Yamamoto, Joe
Omura, Tomohiro
Sakaguchi, Tomoki
Kimura, Norihisa
Ohtaki, Koichi
Ono, Takashi
Suno, Manabu
Asari, Masaru
Ohkubo, Tomoko
Noda, Toshihiro
Awaya, Toshio
Shimizu, Keiko
Matsubara, Kazuo
|
| 書誌情報 |
Neuroscience letters
巻 521,
号 1,
p. 15-19,
発行日 2012-07-01
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0304-3940 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.neulet.2012.05.045 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
A series of oxicam non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be neuroprotective against 1-methyl-4-phenyl pyridinium in human neuroblastoma SH-SY5Y cells via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway independent of cyclooxygenase (COX) inhibition. The present study endeavored to establish this novel effect of meloxicam (MLX), an oxicam NSAID, in a mouse Parkinson's disease (PD) model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Male C57BL/6 mice, which received MPTP (30 mg/kg/day; s.c.) for 5 consecutive days (chronic model) with 10-day follow-up saline administrations, showed significant motor dysfunction in the pole test due to reduced tyrosine hydroxylase (TH) protein levels in the brain on day 16 after MPTP/saline treatment. Daily coadministrations of MLX (10mg/kg/day; i.p.) and MPTP for the first 5 days and follow-up 10 days with MLX administrations alone (MPTP/MLX treatment) significantly ameliorated MPTP-induced behavioral abnormalities in mice. Concomitant decreases of TH protein levels in the striatum and midbrain of MPTP/MLX-treated mice were not only significantly (p<0.01 and p<0.05, respectively) ameliorated but phosphorylated Akt (pAkt473) expression in the midbrain was also significantly (p<0.01) increased in the midbrain when compared with MPTP/saline-treated mice. These results suggest that MLX, an oxicam NSAID, attenuated dopaminergic neuronal death in the experimental MPTP-PD model by maintenance of the Akt-signaling. Oxicam NSAIDs may serve as potential drugs for PD treatment via a novel mechanism of action. |
|
言語 |
en |
| 注記 |
|
|
内容記述タイプ |
Other |
|
注記 |
Author |
| 資源タイプ |
|
|
内容記述タイプ |
Other |
|
資源タイプ |
text |
| 著者版フラグ |
|
|
出版タイプ |
AM |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
| ID(XooNIps) |
|
|
|
22617635 |
| 閲覧数(XooNIps) |
|
| ダウンロード数(XooNIps) |
|
|
|
877 |
5065.pdf (182.5 kB)
